The Food and Drug Administration on Thursday approved the first of an eagerly awaited new class of cancer drugs that unleashes the body’s immune system to fight tumors.
The drug, which Merck will sell under the name Keytruda, was approved for patients with advanced melanoma who have exhausted other therapies.
{iframe}http://www.nytimes.com/2014/09/05/business/merck-wins-approval-of-novel-immune-system-drug-for-cancer.html{/iframe}